Naokatsu Ando

National Center For Global Health and Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Year:

2026

Background Bacterial sexually transmitted infections (STIs) like syphilis, chlamydia and gonorrhoea are often asymptomatic but can cause severe complications, including infertility and vertical transmission in cisgender women, particularly female sex workers (FSWs). Sex work is strongly associated with syphilis, with FSWs representing 38% of syphilis cases among Japanese women in 2021. Despite doxycycline’s proven effectiveness in preventing bacterial STIs, its efficacy in high-risk cisgender women remains inconclusive, highlighting the need for targeted STI prevention strategies in this population. Objectives We investigated the effectiveness of doxycycline pre-exposure prophylaxis (doxyPrEP) in preventing STIs and its impact on vaginal flora among FSWs. Participants and methods This retrospective study included 40 FSWs aged ≥18 years who initiated doxyPrEP (100 mg/day) for STI prevention at a private clinic in Tokyo, Japan, between 1 October 2022 and 14 November 2023. Incidence rate ratios (IRR) for chlamydia, gonorrhoea, syphilis, bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC) were estimated using fixed-effects Poisson regression models. Adherence, side effects, and satisfaction were evaluated through follow-up clinical evaluations. Results Overall STI incidence significantly declined from 232.3 to 79.2/100 person-years following doxyPrEP initiation (IRR = 0.33, P = 0.020). The reduction in chlamydia showed marginal statistical significance (IRR = 0.35, P = 0.056), and syphilis cases dropped to zero. Gonorrhoea, BV, and VVC incidence showed no significant changes. Follow-up clinical evaluations indicated high adherence to doxyPrEP, no serious adverse events, and high satisfaction with doxyPrEP. Conclusions DoxyPrEP significantly reduced the overall STI incidence among FSWs without increasing other vaginal infections.

Year:

2025

Year:

2025

Year:

2025

Background Mycoplasma genitalium, which causes sexually transmitted diseases, is increasingly resistant to key antibiotics such as macrolides and quinolones, posing a challenge for treatment. Objectives To assess the effectiveness of prolonged sitafloxacin and doxycycline combination therapy as a new alternative treatment strategy for highly drug-resistant M. genitalium strains Methods A prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, from 1 January 2020 to 31 October 2022. Patients with M. genitalium urogenital or rectal infections and those who did not receive the initial sitafloxacin monotherapy were included. Patients were administered sitafloxacin and doxycycline for 21 days as salvage therapy. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations. Results Twenty-seven patients received the combination therapy. All M. genitalium strains available for resistance analysis had parC (24/24) and macrolide resistance-associated (25/25) mutations, and 68% (17/25) had gyrA mutations. The overall cure rate was 77.8%. For strains with concurrent parC and gyrA mutations, the cure rate was 68.8% (P = 0.053) compared with that for monotherapy (37.5%). Conclusions Prolonged combination therapy is highly effective against M. genitalium strains with concurrent parC and gyrA mutations. Future research should focus on establishing the optimal treatment duration and monitoring the risk of resistance.

Year:

2025

Year:

2025

Background Giardiasis and cryptosporidiosis are often misdiagnosed by stool ova and parasite test (classical O&P). Multiplex PCR and rapid antigen immunochromatography (rapid-IC) could offer high accuracy; however, its cost and restricted coverage, especially for parasites, limit their use. This study evaluated the efficacy of newly developed “fluorescent antibody microscopy (FAM)” for these protozoa. Methodology/Principal Findinges DyLight 488-conjugated antibodies against Giardia cysts and Cryptosporidium oocysts were used for FAM examination. Diagnostic accuracy was assessed by reference to multiplex PCR results and compared with that of rapid-IC. FAM identified Giardia and/or Cryptosporidium in 35 of 694 stool samples tested. Also, FAM-negative stools examined in a randomly chosen month (49 samples) were selected as negative control. For Giardia , all FAM results were identical to those of rapid-IC, including three false negatives [100% positive predictive value (PPV), and 95.2% negative predictive value (NPV)]. For Cryptosporidium , FAM showed 100% PPV, and 98.6% NPV, which were comparable with those of rapid-IC. Conventional PCR for Giardia sequences produced negative results for three samples considered to yield FAM false negative, raising another possibility of multiplex PCR false positives. Conclusions/Significance Concurrent use of FAM with classical O&P, which strengthens diagnostic accuracy for Giardiasis/Cryptosporidiosis, is an option for cost-effective, practical diagnosis of enteric parasites. Author summary Giardiasis and Cryptosporidiosis are often misdiagnosed through traditional stool tests. Although multiplex-PCR and rapid antigen tests (rapid-IC) offer high accuracy, their cost and limited parasite coverage restrict their use. To overcome these challenges, we developed a new diagnostic method named “Fluorescent Antibody Microscopy (FAM).” This study evaluated the diagnostic accuracy of FAM by using multiplex-PCR as a reference standard and compared it with rapid-IC. For Giardia, FAM’s results were identical to rapid-IC, including three false negatives (100% PPV and 95.2% NPV). Similarly, for Cryptosporidium, FAM showed high diagnostic accuracy (100% PPV and 98.6% NPV), comparable to rapid-IC. Furthermore, in some cases, the concomitant use of bright-field microscopic examination occasionally identified enteric parasites, which were not covered by multiplex-PCR. Our results highlight that morphological parasitical identification with FAM may provide a cost-effective diagnostic strategy for enteric parasites, offering high accuracy for Giardia and Cryptosporidium.

Year:

2025

Background Toxoplasmic encephalitis (TE) and tuberculoma are the leading causes of ring-enhancing brain lesions in patients with human immunodeficiency virus (HIV) infection. Because imaging findings of the two conditions overlap and cerebrospinal fluid (CSF) tests lack sensitivity, timely diagnosis is critical. Herein, we report the rare case of a patient with HIV infection and miliary tuberculosis who developed intracranial mass lesions after antiretroviral therapy (ART) initiation with high-dose prednisolone administration. Case presentation A 53-year-old Nepalese man who had been living in Japan was diagnosed with HIV infection (CD4 count, 146 cells/µL) and miliary tuberculosis. Four-drug rifabutin-based therapy was initiated. However, trimethoprim–sulfamethoxazole (TMP–SMX) prophylaxis was discontinued because of a rash and replaced with monthly pentamidine. ART (dolutegravir/lamivudine) was initiated 3 weeks later. Prednisolone (60 mg/day) was administered for refractory tuberculous ascites, and the dose was tapered over 6 weeks. Eight weeks after ART, the patient developed a headache, and laboratory tests revealed a CD4 count of 384 cells/µL. Magnetic resonance imaging (MRI) revealed right frontal ring-enhancing lesions. CSF was acellular; polymerase chain reaction yielded negative results for several pathogens including Mycobacterium tuberculosis and positive results for Toxoplasma gondii . After a 5-day graded TMP–SMX desensitization, the patient received full-dose therapy for 6 weeks, followed by secondary prophylaxis. The patient’s headache resolved, and repeat MRI after 2 weeks revealed marked regression of the lesions. No radiological relapse was observed 3 months after treatment completion. Conclusions TE can emerge during immune recovery at CD4 counts > 100 cells/µL when corticosteroid administration coincides with early ART. In patients receiving tuberculosis treatment who develop new brain lesions soon after ART, T. gondii polymerase chain reaction and prompt antiparasitic therapy should be pursued. Rifabutin permits concomitant use of dolutegravir, and TMP–SMX desensitization allows effective treatment and prophylaxis.

Year:

2025

Background Despite effective antiretroviral therapy, patients with human immunodeficiency virus type-1 (HIV) suffer from a high frequency of malignancies, but related risk factors remain elusive. Here, we focused on blood-circulating viral protein R (Vpr) of HIV, which induces proinflammatory cytokine production and genotoxicity by exogenous functions. Methods and findings A total 404 blood samples of HIV patients comprising of 126 patients with malignancies (tumor group) and 278 patients without malignancies (non-tumor group), each of 96 samples was first selected by one-to-one propensity score matching. By a detergent-free enzyme-linked immunosorbent assays (detection limit, 3.9 ng/mL), we detected Vpr at a higher frequency in the matched tumor group (56.3%) than in the matched non-tumor group (39.6%) ( P = 0.030), although there was no different distribution of Vpr levels ( P = 0.372). We also detected anti-Vpr immunoglobulin (IgG), less frequently in the tumor group compared with the tumor group (22.9% for tumor group vs. 44.8% for non-tumor group, P = 0.002), and the proportion of patients positive for Vpr but negative of anti-Vpr IgG was significantly higher in the tumor group than in the non-tumor group (38.6% vs. 15.6%, respectively, P < 0.001). Additionally, Interleukin-6 (IL-6), the levels of which were high in HIV-1 infected patients ( P < 0.001) compared to non-HIV-infected individuals, was significantly higher in advanced cases of tumors ( P < 0.001), and IL-6 level was correlated with Vpr in the non-tumor group ( P = 0.010). Finally, multivariate logistic regression analysis suggested a positive link of Vpr with tumor occurrence in HIV patients ( P = 0.002). Conclusion Vpr and IL-6 could be risk factors of HIV-1 associated malignancies, and it would be importance to monitor these molecules for well managing people living with HIV-1.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (6)

Yukari Uemura

Section Chief

National Center For Global Health and Medicine

JAPAN
View details

Chang Kweng Lim

Laboratory Chief

National Institute of Infectious Diseases

JAPAN
View details

Masayuki Saijo

Researcher

National Institute of Infectious Diseases

JAPAN
View details

Hiroshi Moro

Associate Professor

Niigata University

JAPAN
View details

Haruka Sakamoto

University of Tokyo

JAPAN
View details

Satoshi Taniguchi

University of Tokyo

JAPAN
View details